{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"}]}],"title":"Pre-Dose Day 1 (n = 260)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.35","value":"4.3"}]}],"title":"Post-Dose Day 1 (n = 255)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.66","value":"53.0"}]}],"title":"Pre-Dose Day 22 (n = 204)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.67","value":"54.0"}]}],"title":"Post-Dose Day 22 (n = 221)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.13","value":"54.4"}]}],"title":"Pre-Dose Day 43 (n = 166)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.28","value":"54.4"}]}],"title":"Post-Dose Day 43 (n = 170)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.79","value":"57.4"}]}],"title":"Pre-Dose Day 64 (n = 141)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.29","value":"57.7"}]}],"title":"Post-Dose Day 64 (n = 138)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.62","value":"55.0"}]}],"title":"Pre-Dose Day 106 (n = 77)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.36","value":"56.3"}]}],"title":"Post-Dose Day 106 (n = 75)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.13","value":"51.8"}]}],"title":"Pre-Dose Day 148 (n = 38)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.55","value":"53.3"}]}],"title":"Post-Dose Day 148 (n = 39)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.6","value":"53.6"}]}],"title":"Pre-Dose Day 190 (n = 9)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.16","value":"50.5"}]}],"title":"Post-Dose Day 190 (n = 9)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"}],"units":"Participants"}],"description":"The pharmacokinetics of vemurafenib were assessed at the beginning of each 21-day cycle using pre-dose and 2-4 hours post-dose sampling.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"OG000","title":"Vemurafenib"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) analysis population included all participants who received vemurafenib and provided valid PK assessments. The PK population at specific time points varied depending on the availability of confirmed dosing and PK assessment times. \"n\" indicates the number of participants with available PK data at each time point.","reportingStatus":"POSTED","timeFrame":"Plasma samples were collected before the morning dose (troughs) and 2-4 hours after the morning dose at the beginning of each cycle (Days 1, 22, 43, 64, 106, 148 and 190).","title":"Pre and Post-dose Plasma Vemurafenib Concentration by Study Day","type":"SECONDARY","unitOfMeasure":"μg/mL"}